Drug Interactions between Mifeprex and palovarotene
This report displays the potential drug interactions for the following 2 drugs:
- Mifeprex (mifepristone)
- palovarotene
Interactions between your drugs
miFEPRIStone palovarotene
Applies to: Mifeprex (mifepristone) and palovarotene
GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and adverse effects of palovarotene, which is primarily metabolized by the isoenzyme. Concomitant use of ketoconazole, a potent CYP450 3A4 inhibitor, with palovarotene at steady-state plasma levels increased its peak plasma concentration (Cmax) and systemic exposure (AUC) by 121% and 212%, respectively. Increased concentrations of palovarotene may increase the risk of adverse reactions such as dry skin, dry lips, alopecia, pruritus, erythema, paronychia, cellulitis, decubitus ulcer, xerophthalmia, night blindness, depression, mood alterations, and pseudotumour cerebri (benign intracranial hypertension).
MANAGEMENT: According to the manufacturer, concomitant use of palovarotene with potent CYP450 3A4 inhibitors should generally be avoided.
References (2)
- (2022) "Product Information. Sohonos (palovarotene)." Ipsen Biopharmaceuticals Canada inc, 1
- (2023) "Product Information. Sohonos (palovarotene)." Ipsen Biopharmaceuticals, Inc
Drug and food interactions
palovarotene food
Applies to: palovarotene
GENERALLY AVOID: Grapefruit, pomelo, grapefruit hybrids, and juices or supplements containing these fruits may increase the plasma concentrations of palovarotene. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in these fruits. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with these fruits. Concomitant use of erythromycin, a moderate CYP450 3A4 inhibitor, with palovarotene at steady-state plasma levels increased its peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.6 and 2.5-fold, respectively. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased concentrations of palovarotene may increase the risk of adverse effects such as dry skin, dry lips, alopecia, pruritus, erythema, paronychia, cellulitis, decubitus ulcer, xerophthalmia, night blindness, depression, mood alterations, and pseudotumour cerebri (benign intracranial hypertension).
ADJUST DOSE: Food increases oral absorption of palovarotene.
MANAGEMENT: The manufacturer advises that concomitant use of palovarotene with grapefruit, pomelo, grapefruit hybrids and juices or supplements containing these fruits should be avoided. To ensure maximal absorption, palovarotene should be administered with food.
References (2)
- (2022) "Product Information. Sohonos (palovarotene)." Ipsen Biopharmaceuticals Canada inc, 1
- (2023) "Product Information. Sohonos (palovarotene)." Ipsen Biopharmaceuticals, Inc
miFEPRIStone food
Applies to: Mifeprex (mifepristone)
ADJUST DOSING INTERVAL: Food may significantly increase the plasma concentrations of mifepristone.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of mifepristone. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, it should be taken with food to achieve consistent plasma drug levels. Patients should be advised to avoid consuming grapefruit or grapefruit juice during treatment with mifepristone, as it may cause increased adverse effects such as headache, dizziness, fatigue, nausea, vomiting, cramping, diarrhea, hypokalemia, adrenal insufficiency, vaginal bleeding, arthralgia, peripheral edema, and hypertension. Because mifepristone is eliminated slowly from the body, the interaction with grapefruit juice may be observed for a prolonged period.
References (2)
- (2001) "Product Information. Mifeprex (mifepristone)." Danco Laboratories
- (2012) "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.